<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
   xmlns:content="http://purl.org/rss/1.0/modules/content/"
   xmlns:dc="http://purl.org/dc/elements/1.1/"
   xmlns:atom="http://www.w3.org/2005/Atom"
   xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
   xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
   xmlns:company="http://purl.org/rss/1.0/modules/company"
>
	<channel>
		<title>Latest News - Market Wire News</title>
		<atom:link href="https://marketwirenews.com/rss/news-releases/?s=tlsa" rel="self" type="application/rss+xml" />
		<link>https://marketwirenews.com</link>
		<description>Market Wire News RSS News Feed for Tiziana Life Sciences Ltd (NASDAQ: TLSA)</description>
		<lastBuildDate>Wed, 07 Oct 2026 11:52:55 -0400</lastBuildDate>
		<language>en-US</language>
		<sy:updatePeriod> hourly </sy:updatePeriod>
		<sy:updateFrequency> 60 </sy:updateFrequency>

		<image>
			<url>https://marketwirenews.com/assets/img/icons/favicon-32x32.png</url>
			<title>Market Wire News</title>
			<link>https://marketwirenews.com</link>
			<width>32</width>
			<height>32</height>
		</image>
		<item>
            <title>Market Wire News Hottest Alerts Newsletter</title>
            <link>https://marketwirenews.com/newsletter/</link>
            <pubDate>Wed, 07 Oct 2026 11:52:55 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Subscribe to Market Wire News newsletter for instant real-time stock alerts, breaking financial news, trending stocks, and portfolio updates delivered to your email & mobile.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/newsletter/?v=7134</guid>
          </item>
          <item>
            <title>Market Wire News Trending Stocks</title>
            <link>https://marketwirenews.com/trending-stocks/</link>
            <pubDate>Wed, 07 Oct 2026 11:52:55 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Stock Picks]]></category>
            <category><![CDATA[Stock ALerts]]></category>
            <description><![CDATA[Track today's hottest trending stocks on NASDAQ, NYSE, OTCMKTS & Canadian markets. See massive % gainers, real-time movers, volumes, and linked breaking news updates.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/trending-stocks/?v=7134</guid>
          </item>
          <item>
            <title>Market Wire News Investor Awarenewss</title>
            <link>https://marketwirenews.com/advertise/</link>
            <pubDate>Wed, 07 Oct 2026 11:52:55 -0400</pubDate>
            <dc:creator><![CDATA[Market Wire News]]></dc:creator>
            <category><![CDATA[Invesor Awareness]]></category>
            <category><![CDATA[Investor Releatios]]></category>
            <description><![CDATA[Stock Promoter, Investor Relations, Investor Awareness, Market Wire News, investor brand advertisement services, plans and pricing.]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/advertise/?v=7134</guid>
          </item>
		<item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews July 22, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-4685926601939381.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 22 Jul 2026 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, July 22, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-4685926601939381.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews April 16, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-publication-of-posit-6253228920598244.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 16 Apr 2026 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the publication of positive preclinical data ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-publication-of-posit-6253228920598244.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews April 14, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-late-breaking-poster-5595060300851178.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 14 Apr 2026 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that a late-breaking poster on its Phase 2a study ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-late-breaking-poster-5595060300851178.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews April 01, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-announces-data-showing-nasal-anti-cd3-improv-6769340447511009.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 01 Apr 2026 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive preclinical data highlighting nasal ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-announces-data-showing-nasal-anti-cd3-improv-6769340447511009.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 25, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-new-biomarker-data-s-8221602640121263.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 25 Feb 2026 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces positive new biomarker data from a late-breaki...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-new-biomarker-data-s-8221602640121263.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 20, 2026 11:15:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-the-peer-reviewed-pu-5650307127210439.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 20 Jan 2026 11:15:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label stu...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-the-peer-reviewed-pu-5650307127210439.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 16, 2026 02:45:30 pm</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-closing-of-oversubsc-4954906708983615.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 16 Jan 2026 14:45:30 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the closing of its previously announced Compan...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-closing-of-oversubsc-4954906708983615.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 16, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-registered-direct-of-6937909721207956.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 16 Jan 2026 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best efforts registered di...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-registered-direct-of-6937909721207956.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 09, 2026 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-9th-annual-n-8714507868203974.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 09 Jan 2026 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D;), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that Chief Executive Officer Ivor Elrifi will ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-9th-annual-n-8714507868203974.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 29, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-files-annual-safety-report-for-intranasal-fo-8934129507224701.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 29 Dec 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposure    FDA denial of Sanofi&#x2019;s tolebrutinib for nrSPMS shows need for safe therapy     BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:  TLSA ) (&#x201C;...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-files-annual-safety-report-for-intranasal-fo-8934129507224701.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 19, 2025 11:00:45 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-acquisition-of-share-7150456636488891.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 19 Dec 2025 11:00:45 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-acquisition-of-share-7150456636488891.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 17, 2025 10:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-ring-the-closing-bell-at-na-8032965058757691.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 17 Dec 2025 10:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:&#xA0; TLSA ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-ring-the-closing-bell-at-na-8032965058757691.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 17, 2025 08:45:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-doses-first-patient-in-phase-2-7453632210021111.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 17 Dec 2025 08:45:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 Trial    Builds on Recent Evidence of Persistent Neuroinflammation in Alzheimer&#x2019;s Patients Treated with Anti-Amyloid Therapies     BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-doses-first-patient-in-phase-2-7453632210021111.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 15, 2025 07:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-withdrawal-of-propos-7140638707389752.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 15 Dec 2025 07:30:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-withdrawal-of-propos-7140638707389752.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 12, 2025 02:10:00 pm</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-dose-first-patient-in-phase-5603851214411391.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 12 Dec 2025 14:10:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[First Patient Expected to be Dosed Next Week with Intranasal Foralumab         PET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer&#x2019;s Patient on Leqembi       &#xAE;       (Lecanemab) Anti-Amyloid Therapy         BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Science...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-dose-first-patient-in-phase-5603851214411391.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews December 02, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-plans-to-spinout-il-6-asset-in-8408453704728824.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 02 Dec 2025 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies, today announced that it intends to develop its fully human anti-IL-6 rece...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-plans-to-spinout-il-6-asset-in-8408453704728824.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews November 25, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-nasal-foralumab-phase-2-clinic-4932296691190300.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 25 Nov 2025 08:30:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal for...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-nasal-foralumab-phase-2-clinic-4932296691190300.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews November 13, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-jefferies-global-8661492977452610.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 13 Nov 2025 08:30:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-jefferies-global-8661492977452610.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews November 04, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/aquestive-therapeutics-announces-leadership-expansio-8764555012805134.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 04 Nov 2025 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[Changes strategically aligned to support planned launch of Anaphylm&#x2122; (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company&#x2019;s ongoing development initiatives         Matthew Davis, M.D., RPh will join immediately as Chief Development Officer       ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/aquestive-therapeutics-announces-leadership-expansio-8764555012805134.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews October 29, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-bio-europe-in-vi-7397322427597254.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 29 Oct 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-bio-europe-in-vi-7397322427597254.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews September 30, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-invited-to-attend-life-science-5868289194335586.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 30 Sep 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-invited-to-attend-life-science-5868289194335586.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews September 25, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-to-advance-tzls-501-its-fully-human-il-6r-mo-9004036060563725.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 25 Sep 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), today announces it will advance its second asset, a fully human anti-IL-6 receptor (&#x201C;IL-6R&#x201D;) monoclonal antibody, TZLS-501. There has ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-to-advance-tzls-501-its-fully-human-il-6r-mo-9004036060563725.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews September 24, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-poster-presentation--5516055075273508.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 24 Sep 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-poster-presentation--5516055075273508.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews September 15, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/department-of-defense-awards-grant-to-advance-tizian-7163275078700083.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 15 Sep 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/department-of-defense-awards-grant-to-advance-tizian-7163275078700083.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews September 09, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-8445053990848895.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 09 Sep 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-8445053990848895.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews August 14, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-doses-first-patient-in-phase-2-8206127877164602.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 14 Aug 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-doses-first-patient-in-phase-2-8206127877164602.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews August 11, 2025 09:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/fda-approves-tiziana-life-sciences-phase-2-ind-for-m-6210155297198281.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 11 Aug 2025 09:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/fda-approves-tiziana-life-sciences-phase-2-ind-for-m-6210155297198281.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews July 21, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-immunologic-analysis-8804099909759615.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 21 Jul 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-immunologic-analysis-8804099909759615.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews June 13, 2025 10:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-expands-phase-2-clinical-trial-4852564556510587.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 13 Jun 2025 10:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-expands-phase-2-clinical-trial-4852564556510587.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews June 13, 2025 08:30:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-bio-internat-7364862239008298.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 13 Jun 2025 08:30:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-bio-internat-7364862239008298.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews May 23, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-interview-highlighti-8293303644240560.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 23 May 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-interview-highlighti-8293303644240560.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews May 15, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/journal-of-clinical-nuclear-medicine-publishes-resul-8705298150173128.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 15 May 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human,...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/journal-of-clinical-nuclear-medicine-publishes-resul-8705298150173128.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews May 12, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-6174636447428611.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 12 May 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human a...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-purchase-of-shares-b-6174636447428611.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews May 09, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-significant-reductio-6671840391432700.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 09 May 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human ...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-significant-reductio-6671840391432700.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews May 06, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-comprehensive-positi-8194052906946257.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 06 May 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients.         All patients experienced stabilization of Expanded Disability Status Scale (EDSS) scores.         TSPO-PET imaging showed significant reductions in mic...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-comprehensive-positi-8194052906946257.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews April 23, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-university-of-massac-6401929428290337.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 23 Apr 2025 07:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-university-of-massac-6401929428290337.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews April 02, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-johns-hopkins-univer-5380738476015005.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 02 Apr 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-johns-hopkins-univer-5380738476015005.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews March 25, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-yale-university-comm-7206565823055069.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 25 Mar 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-yale-university-comm-7206565823055069.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews March 17, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-37th-annual--8496995498993646.html?utm_source=rss-news-releases</link>
            <pubDate>Mon, 17 Mar 2025 08:00:00 -0400</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-to-present-at-the-37th-annual--8496995498993646.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews March 04, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-files-investigational-new-drug-8200963632547754.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 04 Mar 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-files-investigational-new-drug-8200963632547754.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 27, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-groundbreaking-study-6210426272202690.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 27 Feb 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[Traumatic brain injury is a leading cause of death and disability         Currently, there is no treatment to prevent the long-term effects of traumatic brain injury         Findings could translate into treating intracerebral hemorrhage or stroke           NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-groundbreaking-study-6210426272202690.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 25, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-long-covid-study-to--8827650820848480.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 25 Feb 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-long-covid-study-to--8827650820848480.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 21, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-agreement-for-produc-8568474020714256.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 21 Feb 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-agreement-for-produc-8568474020714256.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 18, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-dosing-of-additional-6675075383212496.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 18 Feb 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:   TLSA   ) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-dosing-of-additional-6675075383212496.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews February 11, 2025 09:15:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-tv-interview-with-fi-8004473154465196.html?utm_source=rss-news-releases</link>
            <pubDate>Tue, 11 Feb 2025 09:15:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-tv-interview-with-fi-8004473154465196.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 23, 2025 03:00:00 pm</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-positive-results-in--5147097719622017.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 23 Jan 2025 15:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-positive-results-in--5147097719622017.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 23, 2025 08:54:12 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-not-to-engage-in-capital-raisi-5396242492999534.html?utm_source=rss-news-releases</link>
            <pubDate>Thu, 23 Jan 2025 08:54:12 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-not-to-engage-in-capital-raisi-5396242492999534.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 22, 2025 04:05:01 pm</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-discovery-of-new-imm-5670714300570990.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 22 Jan 2025 16:05:01 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-discovery-of-new-imm-5670714300570990.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 10, 2025 08:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-announces-reduction-of-side-effects-commonly-5460058424962776.html?utm_source=rss-news-releases</link>
            <pubDate>Fri, 10 Jan 2025 08:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-announces-reduction-of-side-effects-commonly-5460058424962776.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item><item>
            <title>$TLSA Tiziana Life Sciences Ltd #MWN #BreakingNews January 08, 2025 07:00:00 am</title>
            <link>https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-review-article-publi-7882916927918280.html?utm_source=rss-news-releases</link>
            <pubDate>Wed, 08 Jan 2025 07:00:00 -0500</pubDate>
            <dc:creator><![CDATA[GlobeNewswire]]></dc:creator>
            <category><![CDATA[TLSA]]></category>
            <category><![CDATA[Tiziana Life Sciences Ltd]]></category>
            <description><![CDATA[NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (&#x201C;Tiziana&#x201D; or the &#x201C;Company&#x201D;), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, ant...]]></description>
            <guid isPermaLink="false">https://marketwirenews.com/stock/tlsa/news/tiziana-life-sciences-announces-review-article-publi-7882916927918280.html?s=tlsa?v=<?php echo 7134;?></guid>
            </item>
	</channel>
</rss>